ANDA 202568, held by Sandoz. Guanfacine Hydrochloride.
As of Nov 21, 2026, ANDA 202568 (Guanfacine Hydrochloride), held by Sandoz, was first approved by FDA on Jun 3, 2015, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 3, 2015 | Original application | Approved |
| Guanfacine HydrochlorideEQ 1MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 3MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 4MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| May 29, 2020 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Jul 30, 2019 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Jul 30, 2019 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Jun 3, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters